Your browser doesn't support javascript.
loading
Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial.
Weiss, Anne; Delavenne, Emilie; Matias, Carina; Lagler, Heimo; Simon, Daniel; Li, Ping; Hansen, Jon U; Dos Santos, Teresa Pires; Jana, Bimal; Priemel, Petra; Bangert, Christine; Bauer, Martin; Eberl, Sabine; Nussbaumer-Pröll, Alina; Anne Österreicher, Zoe; Matzneller, Peter; Quint, Tamara; Weber, Maria; Nielsen, Hanne Mørck; Rades, Thomas; Johansen, Helle Krogh; Westh, Henrik; Kim, Wooseong; Mylonakis, Eleftherios; Friis, Christian; Guardabassi, Luca; Pace, John; Lundberg, Carina Vingsbo; M'Zali, Fatima; Butty, Pascal; Sørensen, Nikolaj; Nielsen, Henrik Bjørn; Toft-Kehler, Rasmus; Guttman-Yassky, Emma; Stingl, Georg; Zeitlinger, Markus; Sommer, Morten.
Afiliación
  • Weiss A; UNION Therapeutics, Hellerup, Denmark.
  • Delavenne E; Novo Nordisk Foundation for Biosustainability, Technical University of Denmark, Lyngby, Denmark.
  • Matias C; UNION Therapeutics, Hellerup, Denmark.
  • Lagler H; UNION Therapeutics, Hellerup, Denmark.
  • Simon D; Department of Medicine 1, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Wien, Austria.
  • Li P; UNION Therapeutics, Hellerup, Denmark.
  • Hansen JU; UNION Therapeutics, Hellerup, Denmark.
  • Dos Santos TP; Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.
  • Jana B; Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg C, Denmark.
  • Priemel P; Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg C, Denmark.
  • Bangert C; Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark.
  • Bauer M; Department of Dermatology, Medical University of Vienna, Wien, Austria.
  • Eberl S; Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria.
  • Nussbaumer-Pröll A; Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria.
  • Anne Österreicher Z; Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria.
  • Matzneller P; Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria.
  • Quint T; Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria.
  • Weber M; Department of Dermatology, Medical University of Vienna, Wien, Austria.
  • Nielsen HM; Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria.
  • Rades T; Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark.
  • Johansen HK; Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark.
  • Westh H; Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
  • Kim W; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Mylonakis E; Hvidovre Hospital, Hvidovre, Denmark.
  • Friis C; Warren Alpert Medical School of Brown University, Division of Infectious Diseases, Rhode Island Hospital, Providence, Rhode Island, USA.
  • Guardabassi L; Warren Alpert Medical School of Brown University, Division of Infectious Diseases, Rhode Island Hospital, Providence, Rhode Island, USA.
  • Pace J; Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg C, Denmark.
  • Lundberg CV; Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg C, Denmark.
  • M'Zali F; UNION Therapeutics, Hellerup, Denmark.
  • Butty P; Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.
  • Sørensen N; University of Bordeaux, Bordeaux Cede.
  • Nielsen HB; CEVA Santé Animale, Libourne, France.
  • Toft-Kehler R; Clinical Microbiomics, Copenhagen, Denmark.
  • Guttman-Yassky E; Clinical Microbiomics, Copenhagen, Denmark.
  • Stingl G; UNION Therapeutics, Hellerup, Denmark.
  • Zeitlinger M; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Sommer M; Department of Dermatology, Medical University of Vienna, Wien, Austria.
Clin Transl Med ; 12(5): e790, 2022 05.
Article en En | MEDLINE | ID: mdl-35522900
BACKGROUND: In patients with atopic dermatitis (AD), Staphylococcus aureus frequently colonizes lesions and is hypothesized to be linked to disease severity and progression. Treatments that reduce S. aureus colonization without significantly affecting the skin commensal microbiota are needed. METHODS AND FINDINGS: In this study, we tested ATx201 (niclosamide), a small molecule, on its efficacy to reduce S. aureus and propensity to evolve resistance in vitro. Various cutaneous formulations were then tested in a superficial skin infection model. Finally, a Phase 2 randomized, double-blind and placebo-controlled trial was performed to investigate the impact of ATx201 OINTMENT 2% on S. aureus colonization and skin microbiome composition in patients with mild-to-severe AD (EudraCT:2016-003501-33). ATx201 has a narrow minimal inhibitory concentration distribution (.125-.5 µg/ml) consistent with its mode of action - targeting the proton motive force effectively stopping cell growth. In murine models, ATx201 can effectively treat superficial skin infections of methicillin-resistant S. aureus. In a Phase 2 trial in patients with mild-to-severe AD (N = 36), twice-daily treatment with ATx201 OINTMENT 2% effectively reduces S. aureus colonization in quantitative colony forming unit (CFU) analysis (primary endpoint: 94.4% active vs. 38.9% vehicle success rate, p = .0016) and increases the Shannon diversity of the skin microbiome at day 7 significantly compared to vehicle. CONCLUSION: These results suggest that ATx201 could become a new treatment modality as a decolonizing agent.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones Estafilocócicas / Dermatitis Atópica / Staphylococcus aureus Resistente a Meticilina / Microbiota Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Clin Transl Med Año: 2022 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones Estafilocócicas / Dermatitis Atópica / Staphylococcus aureus Resistente a Meticilina / Microbiota Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Clin Transl Med Año: 2022 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Estados Unidos